What is the Prostate Health Index?
The Prostate Health Index (phi) is an FDA-approved blood test that combines three PSA measurements—total PSA, free PSA, and [-2]proPSA—into a single calculated score to improve the detection of clinically significant prostate cancer in men with PSA levels between 4-10 ng/mL. 1
How phi Works
Phi uses a mathematical formula that integrates:
- Total PSA (tPSA)
- Free PSA (fPSA)
- [-2]proPSA (proPSA)
The formula calculates: phi = ([-2]proPSA/fPSA) × √tPSA 2
Clinical Performance and FDA Approval
Phi received FDA approval in 2012 specifically for men with serum PSA values between 4 and 10 ng/mL. 1 The evidence supporting this approval demonstrated:
- Approximately double the sensitivity of the standard free-to-total PSA ratio (fPSA/tPSA) for cancer detection in men with PSA 2-10 ng/mL 1
- Area under the curve (AUC) of 0.72 for discriminating high-grade (Gleason ≥7) cancer from low-grade cancer or negative biopsy 1
- Strong correlation with cancer grade, making it useful for identifying aggressive disease 1
More recent multicenter studies confirm phi outperforms its individual components, with AUC of 0.708 for overall prostate cancer detection and 0.707 for Gleason ≥7 disease 3.
When to Use phi
Primary Indications:
Phi functions as a "reflex test"—not a first-line screening tool—to inform biopsy decisions when PSA is already elevated. 2 The NCCN guidelines recommend considering phi in:
- Men with PSA >3.0 ng/mL who have not yet undergone biopsy 2, 1
- Men with at least one prior negative biopsy who remain at higher risk 2, 1
Specific Clinical Scenarios:
Use phi when the patient and physician wish to further define the probability of high-grade cancer before proceeding to biopsy, particularly in men with PSA 3-10 ng/mL 1. A phi score >35 is strongly suspicious for prostate cancer 2, 1.
Clinical Utility: Reducing Unnecessary Biopsies
At the 90% sensitivity cutpoint (phi <28.6), 30.1% of patients could avoid unnecessary biopsy for benign disease or insignificant prostate cancer, compared to only 21.7% using percent free PSA alone 3. This represents a meaningful reduction in the harms of overdetection and overtreatment.
When incorporated into multivariable risk models with age, previous biopsy status, prostate volume, and PSA, phi achieves AUC of 0.746 for aggressive prostate cancer, with superior net benefit on decision-curve analysis 4.
Integration with Other Diagnostic Tools
Phi can be used alongside—but not replaced by—other assessment tools:
- MRI: Phi may serve as a triage tool before multiparametric MRI, with a cutoff of 30 showing 90% sensitivity for predicting PI-RADS ≥3 lesions 5
- Risk calculators: Adding phi significantly improves the predictive accuracy of the PCPT and ERSPC risk calculators for aggressive disease 4
- Other biomarkers: Phi can be considered alongside percent free PSA, 4Kscore, and PCA3, though each has different optimal use cases 2, 1
Important Caveats
- Phi is NOT intended as a standalone screening test for the general population 2
- Results must be interpreted in context with other clinical factors including age, family history, DRE findings, and patient preferences 2
- No single cutpoint threshold has been universally established; phi results should inform shared decision-making between patient and physician 1
- The test requires serum collection before DRE or prostate manipulation to ensure accurate measurement of PSA isoforms
Bottom Line
Phi represents a validated tool to improve specificity for clinically significant prostate cancer detection, helping to reduce unnecessary biopsies while maintaining high sensitivity for aggressive disease. Its greatest value lies in the "gray zone" of PSA 4-10 ng/mL, where it provides actionable information to guide biopsy decisions and potentially spare men from the morbidity of unnecessary procedures.